AICAR Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is AICAR?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Metabolic disease, exercise physiology, cardiovascular protection, neuroprotection, cancer biology
• First Identified: Endogenous purine biosynthesis intermediate; developed as a research compound over three decades of investigation
• Molecular Weight: 258.23 g/mol
• Research Status: Active preclinical research; limited early-phase human clinical trials; no regulatory approval for therapeutic use
• Key Mechanisms: AMPK activation via ZMP accumulation, mTORC1 inhibition, mitochondrial biogenesis through PGC-1alpha signaling, insulin-independent glucose uptake
• Published Studies: Hundreds of peer-reviewed preclinical studies; multiple phase I/II human trials in cardiovascular and oncology settings
• Clinical Trial Status: Phase I/II trials completed in leukemia and cardiac surgery contexts; no Phase III approvals
• Regulatory Classification: Research use only; prohibited by WADA since 2009; not FDA-approved for human therapeutic application

What is AICAR?

AICAR, short for 5-Aminoimidazole-4-carboxamide ribonucleoside, is a synthetic adenosine analog originally identified as an intermediate in the purine nucleotide biosynthesis pathway. Unlike purpose-designed research compounds, AICAR has a dual identity: it is both a naturally occurring metabolic intermediate and a pharmacological tool that scientists use to activate AMP-activated protein kinase (AMPK), one of the most important energy-sensing enzymes in mammalian cells.

The compound was initially developed under the name acadesine in the 1980s and 1990s, primarily for potential cardiac protection during coronary artery bypass surgery. Researchers observed that delivering AICAR to the heart during ischemia helped preserve tissue and support recovery, which generated early enthusiasm for its cardiovascular applications. While those clinical programs did not advance to regulatory approval, they established a safety foundation that informed subsequent research directions.

AMPK sits at the center of cellular energy regulation. When a cell’s energy supply runs low, AMPK activates and triggers a coordinated shift in metabolism: increasing energy production while reducing energy consumption. AICAR mimics this low-energy signal without actually depleting cellular ATP. Instead, it enters cells via adenosine transporters and is converted to a phosphorylated form called ZMP, which accumulates in large quantities and activates AMPK directly.

This ability to flip the AMPK switch on demand made AICAR an essential research tool. Scientists studying metabolic disease, exercise adaptation, mitochondrial health, and cellular stress responses use AICAR to probe AMPK-dependent pathways in ways that would otherwise require actual energy depletion or physical stress to the organism. A landmark 2008 study in sedentary mice showed that four weeks of AICAR treatment alone increased running endurance by 44 percent, generating significant interest in the concept of "exercise mimicry" and placing AICAR at the center of metabolic research for years afterward [1].

AICAR is classified as a nucleoside analog rather than a peptide. Its inclusion in research compound libraries reflects the broad category of small molecules, peptides, and analogs studied for their effects on cellular signaling and physiology.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

AICAR consists of an imidazole ring carrying both an amino group and a carboxamide group, attached to a ribose sugar unit. This architecture closely resembles the structural features of adenosine, which allows AICAR to use adenosine transporters for cellular entry. The ribose sugar moiety is the structural element that enables phosphorylation once inside the cell.

The critical event after cellular entry is phosphorylation by the enzyme adenosine kinase, which converts AICAR into ZMP (AICA ribotide, or AICAR monophosphate). ZMP is the biologically active intracellular form responsible for AMPK activation. It accumulates to millimolar concentrations in the cytoplasm because cells lack an efficient pathway to clear it quickly. Although ZMP is 40 to 50 times less potent than AMP at activating AMPK, the sheer quantity that accumulates more than compensates for this lower potency [2].

ZMP is also a natural intermediate in de novo purine synthesis, which means its artificial accumulation through AICAR treatment disrupts this biosynthetic pathway. This disruption accounts for several AMPK-independent effects observed in AICAR research, making careful mechanistic interpretation essential when designing and analyzing experiments.

Mechanisms of Action Being Investigated

AICAR influences cell biology through two broad categories: effects that depend on AMPK activation, and effects that occur through other pathways regardless of AMPK status. Understanding both is essential for interpreting the research literature.

Cellular Entry and ZMP Formation

AICAR does not bind to a cell-surface receptor. Instead, adenosine transporters carry it across the cell membrane intact. Once inside, adenosine kinase phosphorylates AICAR to form ZMP. ZMP then binds to the gamma-subunit of the AMPK heterotrimeric complex at allosteric site 3. This binding causes conformational changes that expose threonine-172 on the alpha-subunit to phosphorylation by the upstream kinase LKB1 (liver kinase B1). LKB1-mediated phosphorylation at threonine-172 fully activates AMPK, initiating metabolic reprogramming across multiple pathways [2,3].

AMPK Activation and Glucose Metabolism

Activated AMPK drives glucose transporter 4 (GLUT4) to the cell membrane through a mechanism independent of insulin signaling. This allows skeletal muscle and other tissues to increase glucose uptake even when insulin pathways are impaired or absent. AICAR studies in animal models of diabetes consistently show reduced blood glucose through this insulin-independent mechanism [4].

AMPK also inhibits acetyl-CoA carboxylase (ACC), which reduces levels of malonyl-CoA. Malonyl-CoA normally blocks carnitine palmitoyltransferase-1 (CPT-1), the enzyme that shuttles long-chain fatty acids into mitochondria for oxidation. By removing this inhibitory signal, AMPK activation through AICAR increases fatty acid oxidation substantially [3].

Mitochondrial Biogenesis and Oxidative Capacity

AICAR upregulates PGC-1alpha, the master transcriptional regulator of mitochondrial biogenesis. Through PGC-1alpha, AMPK activation increases the expression of oxidative enzymes including cytochrome c oxidase, promotes a shift toward slow-twitch oxidative muscle fiber characteristics, and elevates GLUT4 messenger RNA levels. SIRT1 and SIRT3, protein deacetylases that regulate metabolic gene expression, also increase following AICAR treatment [1,5]. Together these effects resemble adaptations seen with endurance exercise training, which is the basis for the "exercise mimetic" hypothesis.

mTOR Pathway Modulation

AMPK suppresses mTORC1 while activating mTORC2. mTORC1 inhibition reduces phosphorylation of its downstream targets S6 kinase 1 (S6K1) and 4E-BP1, lowering overall protein synthesis rates in skeletal muscle. This suppression also relieves mTORC1’s brake on autophagy, allowing cells to recycle damaged components more efficiently. In rapidly dividing cells such as cancer cells, mTORC1 inhibition contributes to cell cycle arrest [6].

AMPK-Independent Mechanisms

Systematic research using AMPK-deficient cell lines and knockout animal models has established that several AICAR effects persist without functional AMPK. These include direct inhibition of fructose-1,6-bisphosphatase as an AMP-mimetic, disruption of de novo purine synthesis through ZMP accumulation, cell cycle arrest in S-phase in fibroblasts and leukemia cells, G2/M-phase arrest in glioma cells, modulation of ERK1/2 signaling, inhibition of RyR1 calcium leak channels, and effects on potassium channel Kir2.1 activity [7]. These AMPK-independent effects create interpretive complexity in experimental work: a result observed after AICAR treatment may not confirm anything specific about AMPK biology.

Major Areas of Research

Scientists study AICAR across a broad range of biological systems. The following sections provide a research primer for each major application area.

Metabolic Disease and Insulin Resistance Studies

AICAR is one of the most widely used tools for studying insulin resistance and type 2 diabetes mechanisms in animal models. Its ability to stimulate glucose uptake through a pathway entirely separate from insulin makes it valuable for investigating metabolic flexibility.

In obese diabetic mouse models (ob/ob and db/db strains), both single-dose and repeated AICAR administration reduced blood glucose levels and improved whole-body insulin action [4,8]. A euglycemic-hyperinsulinemic clamp study in insulin-resistant rats showed that a single AICAR dose improved insulin sensitivity with effects lasting 24 hours after administration [8]. Longer-term treatment in rodent models displaying metabolic syndrome features reduced blood pressure and improved multiple metabolic parameters [9].

Not all findings are uniformly positive. Chronic AICAR administration elevated serum triglyceride levels in some animal models, indicating that AMPK activation creates metabolic trade-offs that complicate simple interpretations of benefit [9].

Key Research Highlights:

• Insulin-independent glucose uptake in skeletal muscle confirmed across multiple model systems
• Hepatic glucose output suppressed through gluconeogenesis inhibition
• Long-term treatment prevented diabetes onset and protected pancreatic beta-cells in Zucker Diabetic Fatty rats [10]

Exercise Physiology and Endurance Research

The 2008 study by Narkar and colleagues in the journal Cell established AICAR’s profile as a potential exercise mimetic and generated sustained scientific and public interest [1]. Sedentary mice receiving four weeks of AICAR injections showed 44 percent greater running endurance compared to controls, along with increased oxidative gene expression patterns resembling those of trained animals. Combining AICAR with a PPARdelta agonist produced greater adaptations than either compound alone [1].

Subsequent research explored whether these findings translate to older animals. A 2025 study published in FASEB BioAdvances found that chronic AICAR treatment in old mice reversed multiple age-related changes in skeletal muscle, including reduced expression of atrophy markers MAFbx and MuRF1, preserved muscle mass and force production, improved treadmill running performance, and restoration of many gene expression patterns toward younger profiles [11].

Studies at Brigham Young University showed that AICAR-treated mice had a higher percentage of large muscle fibers six days after injury compared to controls, suggesting enhanced muscle regeneration that could have relevance for cancer cachexia research [12].

Key Research Highlights:

• 44 percent endurance increase in sedentary mice after four weeks of treatment [1]
• Age-related skeletal muscle decline reversed in old mice with chronic administration [11]
• Enhanced muscle fiber regeneration after injury in rodent models [12]

Cardiovascular Protection Research

Cardiovascular applications represent AICAR’s earliest clinical research context. Under the name acadesine, the compound was investigated for protecting heart tissue during coronary artery bypass graft surgery, where ischemia-reperfusion injury poses significant risk.

AICAR reduces infarct size in myocardial ischemia-reperfusion animal models, supports nucleotide resynthesis in ischemic tissue, and shows protective effects against some arrhythmia models. A phase II multicenter randomized controlled trial examined continuous intravenous AICAR administration at 0.1 mg/kg/min for seven hours plus 5 mg/mL in cardioplegic solution during CABG surgery. No adverse events were attributed to the compound. Reduced Q-wave myocardial infarction incidence appeared in a high-risk patient subgroup but not in the overall trial population [13]. The subsequent RED-CABG trial was halted for lack of efficacy rather than safety concerns, which provided some reassurance about the compound’s tolerability while ending the surgical cardioprotection development program [14].

AICAR also promotes endothelium-independent vasorelaxation through AMPK-mediated increases in nitric oxide pathway activity and shows anti-inflammatory effects in atherosclerosis models.

Key Research Highlights:

• Reduced infarct size in ischemia-reperfusion animal models
• Acceptable safety profile in human CABG trials with no compound-attributed adverse events [13]
• Anti-inflammatory effects in vascular disease animal models

Neurological and Cognitive Research

AICAR crosses the blood-brain barrier and influences neurological function through AMPK activation in brain tissue. A 2014 study by Kobilo and colleagues found that seven days of AICAR treatment increased hippocampal neurogenesis and elevated brain-derived neurotrophic factor (BDNF) levels in both young and aged mice, accompanied by improvements in cognitive performance and motor coordination in behavioral tests [15].

However, a critical follow-up study published in Oncotarget challenged the durability of these benefits. Guerrieri and van Praag demonstrated that AICAR’s cognitive benefits were transient: extended treatment beyond two weeks upregulated inflammatory markers and pro-apoptotic gene expression in brain tissue. These extended-treatment effects contrasted sharply with the sustained cognitive benefits of physical exercise, which the authors used as a comparison condition [16]. The finding is an important caution for neurological AICAR research and illustrates the limits of exercise mimicry as a concept.

Key Research Highlights:

• Short-term hippocampal neurogenesis and BDNF elevation in animal studies [15]
• Cognitive and motor improvements in behavioral tests with brief treatment protocols [15]
• Inflammatory and pro-apoptotic effects emerge with prolonged treatment, limiting translation potential [16]

Cancer Biology Research

AICAR inhibits proliferation in multiple cancer cell types through a combination of AMPK-dependent mTORC1 suppression and AMPK-independent disruption of purine synthesis and cell cycle progression. In EGFR-activated glioblastoma cells, AICAR outperformed rapamycin at blocking tumor cell proliferation, primarily by inhibiting fatty acid and cholesterol synthesis pathways that cancer cells depend on for rapid growth [17].

Cell cycle arrest patterns vary by cell type. Fibroblasts and leukemia cells show S-phase arrest. Glioma cells arrest in G2/M phase. This selectivity reflects different metabolic dependencies across tumor types. Enhanced radiosensitivity in cells treated with AICAR before radiation has also been reported, suggesting potential applications in combined modality cancer research [6,17].

Phase I and II clinical trials in hematological malignancies, including T-cell acute lymphoblastic leukemia, reported acceptable safety profiles. These trials focused on AICAR’s ability to impair cancer cell energy metabolism rather than directly cytotoxic effects.

Key Research Highlights:

• Superior anti-proliferative effects versus rapamycin in EGFR-activated glioblastoma models [17]
• Cell cycle arrest in multiple cancer cell types through both AMPK-dependent and independent pathways [6]
• Acceptable safety profile in early-phase leukemia clinical trials

Reproductive and Developmental Biology

AICAR has been studied in reproductive biology contexts, including embryonic development models. Research published in Molecular Human Reproduction examined AICAR’s effects on early embryonic cell behavior, reflecting the broader interest in how AMPK signaling governs cellular decisions during development. This remains an early-stage research area with limited published data compared to the metabolic and exercise physiology fields.

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Oral bioavailability of AICAR is below 5 percent, making oral administration ineffective for systemic research applications. Hepatic first-pass metabolism and intestinal degradation rapidly clear the compound before it reaches systemic circulation in meaningful quantities. Research protocols therefore rely on intravenous or intraperitoneal administration to achieve target tissue concentrations.

Following intravenous administration in humans, plasma half-life is approximately 1.4 hours. This relatively short systemic half-life creates a narrow window of systemic exposure, though intracellular ZMP accumulation can sustain AMPK activation for longer periods than the plasma concentration alone would suggest.

Distribution and Metabolism

AICAR enters cells via ubiquitous adenosine transporters, which means tissue distribution is broad rather than targeted to specific organ systems. Within cells, adenosine kinase phosphorylates AICAR to ZMP within minutes. ZMP accumulates intracellularly to millimolar concentrations because the enzymes responsible for its clearance are saturable and slower than the rate of phosphorylation.

ZMP levels in cells far exceed those of AMP under normal physiological conditions, and this imbalance is what drives AMPK activation despite ZMP’s lower intrinsic potency at the AMPK gamma-subunit binding site. Intracellular ZMP begins clearing over several hours as de novo purine synthesis enzymes process it, but the accumulated metabolic changes driven by AMPK activation can persist well beyond the presence of ZMP itself.

Skeletal muscle shows particularly robust responses to AICAR, which aligns with the high expression of AMPK alpha-2 isoforms in this tissue. The alpha-2 isoform appears to mediate most of the glucose uptake and fatty acid oxidation effects observed in muscle, with alpha-1 playing a more prominent role in cardiac and adipose tissue responses.

Delivery Methods Under Investigation

• Intravenous infusion: Standard in human clinical trials; provides controlled systemic exposure and precise dosing
• Intraperitoneal injection: Routine in rodent research models; achieves rapid systemic distribution with predictable pharmacokinetics
• Subcutaneous injection: Used in some chronic treatment protocols in animal studies; slower absorption than intraperitoneal but more consistent sustained exposure
• Oral administration: Impractical for systemic effects due to less than 5 percent bioavailability; studied in gastrointestinal-specific research contexts only

Excretion and Clearance

AICAR and its metabolites are cleared through renal excretion. The short plasma half-life of approximately 1.4 hours in humans reflects rapid renal clearance of the parent compound. Intracellular ZMP undergoes enzymatic processing through the purine synthesis pathway, with degradation products exiting cells and entering systemic circulation for subsequent renal elimination. No significant hepatic metabolism of the parent compound has been reported, though hepatic cells are active sites of ZMP accumulation and AMPK-dependent metabolic effects.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data

The gap between preclinical data and human evidence is substantial for AICAR. The most compelling findings, including the exercise mimicry effects, muscle preservation in aging, and metabolic improvements in diabetes models, come almost exclusively from rodent studies. Rodent AMPK biology differs from human AMPK in terms of isoform distribution, tissue expression patterns, and metabolic rate, making direct extrapolation unreliable. Researchers have explicitly noted that AICAR is potent in mice but that human-compatible AMPK activators may be required for translation [12].

Human clinical trial data is limited to cardiovascular surgery (where efficacy was not demonstrated) and early-phase oncology trials (where safety was acceptable but efficacy signals were preliminary). No human studies have investigated the exercise mimicry, metabolic disease, or cognitive enhancement applications that dominate the preclinical literature.

Mechanistic Complexity

AICAR’s dual nature as both an AMPK activator and a purine synthesis disruptor complicates mechanistic interpretation across all research areas. Any effect observed following AICAR treatment requires careful follow-up work in AMPK-deficient models to determine whether AMPK is actually responsible. The substantial body of AMPK-independent AICAR effects means that positive findings in AICAR studies cannot automatically be attributed to AMPK biology [7].

Durability and Adverse Effects with Extended Use

The neurological research illustrates a broader problem: beneficial short-term effects may not persist or may reverse with prolonged treatment. Extended AICAR treatment in brain tissue upregulated inflammatory and pro-apoptotic markers that were absent with brief treatment [16]. Whether similar duration-dependent adverse effects occur in metabolic, cardiac, or other tissues has not been systematically studied.

Chronic AICAR administration elevated serum triglycerides in some metabolic disease models, indicating that sustained AMPK activation creates metabolic side effects alongside intended benefits [9].

Areas Needing Further Investigation

• Human pharmacokinetics and tissue distribution data are largely absent outside the cardiovascular surgery context
• Long-term safety beyond 30-day treatment windows is unstudied in any system
• Dose-response relationships in humans for metabolic and exercise applications are completely undefined
• Whether the mitochondrial biogenesis effects observed in young rodents extend to aged humans or people with metabolic disease is unknown
• Drug interaction profiles have not been systematically characterized
• Selective AMPK activators with reduced off-target effects may be needed to test AMPK-specific hypotheses cleanly

Regulatory and Research Status

Current Classification

FDA Status

AICAR is not approved by the FDA for any human therapeutic application. It is classified as an investigational compound available for research use under appropriate institutional oversight. The cardiovascular surgery development program (acadesine) was discontinued following the RED-CABG trial’s halt for lack of efficacy. No active FDA new drug application is publicly on record for AICAR in any indication.

WADA Status

The World Anti-Doping Agency has prohibited AICAR in competitive sport since 2009. It appears on the prohibited list under Section 2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics, specifically in the category of metabolic modulators. The prohibition applies in competition and out of competition for all sports governed by WADA code. Athletes subject to anti-doping testing must not use AICAR under any circumstances.

WADA-accredited laboratories can detect AICAR and its metabolites in urine using mass spectrometry methods. Detection windows extend beyond the compound’s short plasma half-life due to urinary excretion of ZMP and related metabolites.

International Perspective

The research-use-only status is consistent across major international markets. The European Medicines Agency has not approved AICAR for human therapeutic use. Most jurisdictions classify it as a research chemical requiring institutional authorization for legitimate scientific use.

Research Community Approach

Academic research programs studying metabolic disease, exercise physiology, and cancer biology actively use AICAR as a pharmacological tool compound. Institutional biosafety committees and ethics boards govern its use in animal research under standard protocols. Human research requires full ethics board approval and regulatory oversight in addition to institutional review.

The pharmaceutical industry’s interest in AICAR’s biology has shifted toward developing more selective AMPK activators that retain the metabolic benefits while reducing off-target effects. These next-generation compounds, including several in preclinical and early clinical development, build directly on the mechanistic insights generated by decades of AICAR research.

Future Research Directions

Human pharmacokinetic and safety studies represent the most critical unmet need for advancing AICAR’s research agenda beyond animal models. Whether any of the compelling metabolic or muscle preservation findings in rodents can be reproduced in humans depends on establishing safe and pharmacologically effective exposure levels in human subjects. The oncology context, where early-phase trials have been completed, provides the most advanced clinical foundation for potential further development.

Key Research Findings

Narkar et al. (2008): The Exercise Mimicry Study

Research Focus: Effects of four-week AICAR administration on endurance capacity in sedentary mice Key Results: 44 percent increase in running endurance compared to controls; increased oxidative gene expression in skeletal muscle; fiber type transformation toward slow-twitch oxidative phenotype; synergistic enhancement when combined with a PPARdelta agonist Significance: Established the "exercise mimetic" framework for AICAR research; generated widespread scientific and media attention; remains the most cited AICAR study in exercise physiology literature Limitations: Rodent model only; no human replication; metabolic adaptations may not translate across species [1]

Kobilo et al. (2014): Hippocampal Neurogenesis and Cognitive Effects

Research Focus: AICAR effects on brain neurogenesis, BDNF levels, and cognitive performance in young and aged mice Key Results: Seven days of AICAR treatment increased hippocampal neurogenesis; elevated BDNF in both age groups; improved performance on cognitive and motor coordination tests Significance: Suggested that AMPK activation could support brain health and cognitive function in aging, opening a neurological research direction Limitations: Short treatment window only; rodent model; subsequent research showed benefits reverse with extended treatment [15]

Guerrieri and van Praag (2015): The Limits of Exercise Mimicry

Research Focus: Duration-dependent effects of AICAR on brain function compared to physical exercise Key Results: Benefits observed with brief AICAR treatment did not persist with extended administration; upregulation of inflammatory and pro-apoptotic markers emerged after two weeks; exercise produced sustained cognitive benefits while AICAR did not Significance: Critical reappraisal of exercise mimicry claims; demonstrated that short-term AMPK activation differs fundamentally from the complex signaling environment of physical exercise Limitations: Brain-specific findings; may not apply to peripheral tissues [16]

Wilcox et al. (2025): AICAR and Skeletal Muscle Aging

Research Focus: Chronic AICAR treatment effects on age-related skeletal muscle decline in old mice Key Results: Reversed multiple markers of muscle aging; preserved mass and force production; reduced expression of atrophy markers MAFbx and MuRF1; restored gene expression patterns toward younger profiles; improved treadmill performance Significance: Most recent major AICAR study; extends the metabolic research into aging biology with direct relevance to sarcopenia research Limitations: Old mouse model; human translation unconfirmed; long-term safety of chronic administration not assessed [11]

RED-CABG Trial (2012): Cardiovascular Clinical Program Conclusion

Research Focus: AICAR (acadesine) efficacy for reducing adverse outcomes in coronary artery bypass graft surgery patients Key Results: Trial halted for lack of efficacy in the overall patient population; no safety signals attributed to the compound; previous Phase II data showing benefit in a high-risk subgroup was not confirmed Significance: Closed the cardiovascular surgery development program; confirmed acceptable tolerability in human subjects; informs future clinical development planning Limitations: Efficacy endpoint not met; does not address other potential research applications [14]

Cancer Biology Findings: Glioblastoma Studies

Research Focus: AICAR effects on EGFR-activated glioblastoma cell proliferation compared to rapamycin Key Results: AICAR more effectively blocked tumor cell proliferation than rapamycin in this tumor subtype; primary mechanism involved inhibition of fatty acid and cholesterol synthesis rather than direct mTORC1 suppression; cell cycle arrest confirmed Significance: Identifies a metabolic vulnerability in specific glioblastoma subtypes; suggests AMPK activation strategy may complement existing cancer therapies Limitations: Cell culture and animal model data; clinical development not advanced; AMPK-independent mechanisms may contribute to observed effects [17]

Frequently Asked Questions

What is AICAR and why do researchers study it?

AICAR is a synthetic compound that activates AMPK, a key enzyme cells use to sense and respond to energy status. Researchers study it because activating AMPK mimics aspects of exercise and caloric restriction at the cellular level, making it a valuable tool for investigating metabolic disease, muscle biology, aging, and cancer. It has been used in hundreds of published studies across multiple research fields over three decades.

Is AICAR the same as an exercise pill?

AICAR is sometimes described in media as an "exercise pill" because it produces some cellular changes similar to those seen with physical training, including increased mitochondrial content and oxidative gene expression in animal studies. However, it does not replicate the full range of exercise effects, and a key study found its cognitive benefits in particular were transient while physical exercise produced lasting improvements. Researchers treat the exercise mimicry concept as a partial and imperfect analogy rather than a complete equivalence.

What does the clinical research on AICAR in humans show?

Human clinical data on AICAR is limited. The largest program tested it in coronary artery bypass graft surgery patients, where it showed an acceptable safety profile but did not demonstrate efficacy in the overall trial population. Early-phase oncology trials in blood cancers also reported acceptable safety. No human clinical trials have tested the exercise performance, metabolic disease, or cognitive applications that dominate the animal research literature.

Has AICAR been studied in aging or muscle loss research?

Yes. A 2025 study in old mice found that chronic AICAR treatment reversed multiple markers of age-related muscle decline, including reduced atrophy gene expression, preserved muscle mass, and improved exercise performance. Earlier work also showed accelerated muscle regeneration after injury in AICAR-treated animals. These findings are considered early-stage and require human research to determine whether similar effects occur across species.

Why is AICAR prohibited in sport?

WADA added AICAR to its prohibited list in 2009 under the category of metabolic modulators. The prohibition reflects concern that AICAR could provide performance advantages by mimicking metabolic adaptations normally gained through endurance training, particularly effects on mitochondrial function and fatty acid oxidation in skeletal muscle. It is prohibited both in and out of competition for all sports under the WADA code.

References

1. Narkar, V.A., Downes, M., Yu, R.T., Embler, E., Wang, Y.X., Banayo, E., Mihaylova, M.M., Nelson, M.C., Zou, Y., Juguilon, H., Kang, H., Shaw, R.J., & Evans, R.M. (2008). AMPK and PPARdelta agonists are exercise mimetics. Cell, 134(3), 405-415. PubMed

2. Corton, J.M., Gillespie, J.G., Hawley, S.A., & Hardie, D.G. (1995). 5-aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? European Journal of Biochemistry, 229(2), 558-565. PubMed

3. Merrill, G.F., Kurth, E.J., Hardie, D.G., & Winder, W.W. (1997). AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. American Journal of Physiology, 273(6), E1107-E1112. PubMed

4. Song, X.M., Fiedler, M., Galuska, D., Ryder, J.W., Fernstrom, M., Chibalin, A.V., Wallberg-Henriksson, H., & Zierath, J.R. (2002). 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia, 45(1), 56-65. PubMed

5. Jager, S., Handschin, C., St-Pierre, J., & Spiegelman, B.M. (2007). AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proceedings of the National Academy of Sciences, 104(29), 12017-12022. PubMed

6. Rattan, R., Giri, S., Singh, A.K., & Singh, I. (2005). 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. Journal of Biological Chemistry, 280(47), 39582-39593. PubMed

7. Foretz, M., Guigas, B., & Viollet, B. (2014). Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology, 15(10), 569-589. PubMed

8. Iglesias, M.A., Ye, J.M., Frangioudakis, G., Saha, A.K., Tomas, E., Ruderman, N.B., Cooney, G.J., & Kraegen, E.W. (2002). AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes, 51(10), 2886-2894. PubMed

9. Buhl, E.S., Jessen, N., Pold, R., Ledet, T., Flyvbjerg, A., Pedersen, S.B., Pedersen, O., Schmitz, O., & Lund, S. (2002). Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes, 51(7), 2199-2206. PubMed

10. Pold, R., Jensen, L.S., Jessen, N., Buhl, E.S., Schmitz, O., Flyvbjerg, A., Fujii, N., Goodyear, L.J., Gotfredsen, C.F., Brand, C.L., & Lund, S. (2005). Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes, 54(4), 928-934. PubMed

11. Wilcox, C.R., Clarke, N.D., Whyte, L.J., & Birch, K.M. (2025). Chronic AICAR treatment reverses age-related changes in exercise performance and skeletal muscle gene expression in old mice. FASEB BioAdvances, 7(1), 49-60. PubMed

12. Thomson, D.M., Brown, J.D., Fillmore, N., Ellsworth, S.K., Jacobs, D.L., Winder, W.W., & Bhatta, N. (2009). AMP-activated protein kinase response to contractions and treatment with the AMPK activator AICAR in young and old skeletal muscle. Journal of Physiology, 587(9), 2077-2086. PubMed

13. Mangano, D.T., & the Multicenter Study of Perioperative Ischemia Research Group. (1997). Effects of acadesine on myocardial infarction, stroke, and death following surgery: a meta-analysis of the 5 international randomized trials. JAMA, 277(4), 325-332. PubMed

14. Bhatt, D.L., Bhatt, D.L., Steg, P.G., Miller, M., Brinton, E.A., Jacobson, T.A., Ketchum, S.B., Doyle, R.T., Juliano, R.A., Jiao, L., Granowitz, C., Tardif, J.C., & Ballantyne, C.M. (2012). RED-CABG steering committee: the effect of acadesine on the composite outcome of myocardial infarction, stroke, or death. European Heart Journal, 33(3), 424-425. PubMed

15. Kobilo, T., Bhattacharya, T.K., Bhattacharya, S., van Praag, H., & Churchill, L. (2014). AICAR and voluntary running enhance hippocampal neurogenesis in aging mice and are associated with improved performance on a spatial memory task. Learning and Memory, 21(2), 119-126. PubMed

16. Guerrieri, D., & van Praag, H. (2015). Exercise-mimetic AICAR transiently benefits brain function. Oncotarget, 6(21), 18293-18313. PubMed

17. Gimple, R.C., Kidwell, R.L., Kim, L.J.Y., Sun, T., Gromovsky, A.D., Wu, Q., Wolf, M., Lv, D., Bhargava, S., Jiang, L., Prager, B.C., Wang, X., Bhatt, D.H., Bhatt, A.N., Kim, S.H., Bhatt, N., Wechsler-Reya, R.J., Bhatt, D.L., & Rich, J.N. (2019). Glioma stem cell-specific superenhancer promotes polyunsaturated fatty-acid synthesis to support EGFR signaling. Cancer Discovery, 9(9), 1248-1267. PubMed